

- **Name:** Jang Ho Cho
- **Current Position & Affiliation:** Clinical Assistant Professor
Division of Oncology, Department of Internal Medicine, Gil Medical Center, College of Medicine, Gachon University, Incheon
- **Country:** Korea

• Educational Background:

Name and Location of Institution	Degree and Year Awarded	Area of Study
EDUCATION		
Medical Doctor, Yonsei Wonju University College of Medicine, Korea	2003.3.-2009.2.	
Master in Medicine, Yonsei University College of Medicine, Seoul, Korea	2012.9.-2017.2.	Internal Medicine (Oncology)
Ph.D. in Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea	2017.3.- 2019.8	Internal Medicine (Oncology)
TRAINING		
Internship, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2009.3.-2010.2.	
Internal Medicine residency, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea	2010.3.-2014.2.	Internal Medicine
Clinical fellowship, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	2017.5.- 2019.2	Hematology-Oncology

• Main Scientific Publications:

(1) Papers in SCI(E)-journals as the first author

1. **Cho JH**, Lim JY, Choi AR, Choi SM, Kim JW, Choi SH, Cho JY. Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Res Treat. 2015 Oct;47(4):697-705. **IF 4.245**
2. **Cho JH**, Lim JY, Cho JY. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. World J Gastroenterol 2017; 23(41): 7407-7414. **IF 3.300**
3. **Cho JH**, Lim JY, Cho JY. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PloS one. 2017;12(10):e0186362. **IF 2.776**
4. **Cho JH**, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018;13(3):e29-e31. **IF 12.460**
5. **Cho JH**, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Late-Onset Cholecystitis with Cholangitis

after Avelumab Treatment in Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018;13(3):e34-e6. **IF 12.460**

6. **Cho JH**, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2019 May;145(5):1341-1349. **IF 3.656**

7. **Cho JH**, Kim JS, Kim ST, Hong JY, Park JO, Park YS, Nam DH, Lee DW, Lee J. Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. PLoS One. 2019 Apr 17;14(4):e0215080. **IF 2.740**

8. **Cho JH**, Kim SY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. Transl Cancer Res 2019;8(5):2107-2112. **IF 1.228**

9. **Cho JH**, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020 Feb 10;38(5):488-495. **IF 44.544**

10. **Cho JH**, Shim JH, Yoon SE, Kim HJ, Kim SH, Ko YH, Lee ST, Kim K, Kim WS, Kim SJ, Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia. Korean J Intern Med. 2021 May;36(3):668-678. **IF 2.884 (2020)**

11. **Cho JH**, Sim MH, Kim SY, Kim K, Lee T, Lee J, Kang WK, Kim ST. Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer. J Cancer Res Ther. 2021 Jul-Sep;17(4):1047-1051. **IF 1.805 (2020)**